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Pancreatic cancer is one of the most aggressive gastrointestinal cancer with less than 10% long-term survivors. The apoptotic pathway
deregulation is a postulated mechanism of carcinogenesis of this tumour. The present study investigated the prognostic role of
apoptosis and apoptosis-involved proteins in a series of surgically resected pancreatic cancer patients. All patients affected by
pancreatic adenocarcinoma and treated with surgical resection from 1988 to 2003 were considered for the study. Patients’ clinical
data and pathological tumour features were recorded. Survivin and Cox-2 expression were evaluated by immunohistochemical
staining. Apoptotic cells were identified using the TUNEL method. Tumour specimen of 67 resected patients was included in the
study. By univariate analysis, survival was influenced by Survivin overexpression. The nuclear Survivin overexpression was associated
with better prognosis (P¼0.0009), while its cytoplasmic overexpression resulted a negative prognostic factor (P¼0.0127). Also, the
apoptotic index was a statistically significant prognostic factor in a univariate model (P¼0.0142). By a multivariate Cox regression
analysis, both the nuclear (P¼0.002) and cytoplasmic (P¼0.040) Survivin overexpression maintained the prognostic statistical value.
This is the first study reporting a statistical significant prognostic relevance of nuclear and cytoplasmic Survivin overexpression in
pancreatic cancer. In particular, patients with high nuclear Survivin staining showed a longer survival, whereas patients with high
cytoplasmic Survivin staining had a shorter overall survival.
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Pancreatic duct cell carcinoma (PDC) is one of the most malignant
gastrointestinal tumours. Once PDC is clinically evident, it
progresses rapidly to develop metastatic lesions and this event
often occurs by the time of diagnosis. Furthermore, this tumour is
usually resistant to conventional chemotherapy and radiation
therapy. The pathogenic mechanisms that regulate this aggressive
growth behavior of PDC still is to be clarified (Satoh et al, 2001).
Apoptosis or programmed cell death plays a critical role in
normal morphogenesis and homeostatic mechanisms in both
normal and neoplastic cells. The suppression of apoptosis, by
aberrantly prolonging cell viability, is considered to contribute to
carcinogenesis and carcinoma progression by facilitating gene
mutations and promoting resistance to immune-based cytotoxicity
(Thompson, 1995).
Apoptosis is implemented by a family of cysteine proteases
known as caspases. These are produced inside the cell as inactive
zymogens and generally must undergo proteolytic processing to
become active proteases (Jaattela, 1999; Nicholson, 1999).
The inhibitors of apoptosis protein (IAPs) are the only known
endogenous caspase inhibitors (Deveraux et al, 1997). They
contain Baculovirus IAP repeat domains, and some of them bind
and potently inhibit activated caspases, including in mammals the
effector caspases-3 and -7 and the initiator caspase-9 (Deveraux
and Reed, 1999).
In addition to Baculovirus IAP repeat domains, several IAPs also
contain a RING domain, which binds ubiquitin-conjugating
enzymes that promote degradation of IAP caspase complexes
(Yang et al, 2000).
Survivin is a member of IAPs family and contains a single
baculovirus IAP repeat (Ambrosini et al, 1997; LaCasse et al, 1998).
It is expressed during human foetal development, but not
detectable in normal adult tissues, except in thymus and placenta.
Its expression has been showed in several neoplasms, including
pancreatic, gastric, colonic, lung, breast, prostatic and bladder
cancers, neuroblastomas, and lymphomas (Adida et al, 1998a;
Ambrosini et al, 1998; Kawasaki et al, 1998; Lu et al, 1998; Swana
et al, 1999; Kobayashi et al, 1999).
For these malignancies, previous studies established that
Survivin is an important mediator in carcinogenesis; it acts as a
resistance factor by inhibiting caspase activity in cells exposed to a
variety of genotoxic stresses such as anticancer drugs and Fas-
ligand (Li et al, 1998, 1999; Tamm et al, 1998).
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sThe prognostic role of apoptosis, pro- and antiapoptotic mole-
cules in human cancer is still a debating matter: previous studies
suggested that the Survivin expression in cancer is associated with
a more aggressive disease and with shorter patients survival (Li,
2003). However, it must be pointed out that besides the increase
of published papers about Survivin in the last 3 years, inconsistent
observations have been reported on this item (Li, 2003).
Other molecules supposed to be involved in the modulation
process of apoptosis in human solid cancer have been investigated
and some of them are tightly related with Survivin. Recently,
Krysan et al have demonstrated that the overexpression of Cox-2
significantly increases the survival of NSCLC cells exposed to
apoptotic stimuli and that the expression of antiapoptotic protein
Survivin has correlated positively correlates with the Cox-2
expression. As a consequence, the authors suggested that in the
Cox-2 overexpressing cells, Survivin is stabilised due to the
lowered ubiquitination levels, which may account for the elevated
apoptosis resistance of these cells (Krysan et al, 2004).
The aim of the present study was to investigate the prognostic
role of Survivin and Cox-2 expression and the modulation of their
apoptotic pathway in a series of 67 pancreatic cancer patients
treated with radical surgical resection. The impact of the Survivin
cellular distribution (nuclear vs cytoplasmic) on prognosis in this
cohort of patients was also evaluated.
PATIENTS AND METHODS
Clinical data and tumour specimen acquisition
In order to obtain the most possible consistent and homogeneous
group of patients, only patients with no macroscopic residual
tumour were considered, were treated at the Catholic University
School of Medicine of Rome and at the University Campus Bio-
Medico of Rome from January 1986 through April 2003. Patients
were staged before surgery by CT-Scan of the thorax, abdomen and
pelvis. If necessary, intraoperative ultrasound of the liver was
performed. Intraoperative staging always confirmed the absence
of distant metastases and of infiltration of mesenteric vessels
and/or portal vein. Preoperative staging showed a tumour of the
pancreatic head in 54 cases (84.7%), of the body and/or of the tail
in six cases (8.9%) and a diffuse neoplasm in seven (10.4%). All
patients underwent surgical resection with standard lymphade-
nectomy. All patients affected by diffuse tumour underwent total
pancreatectomy. In the presence of a body and/or tail tumour,
distal pancreatectomy was always performed. Finally, in case
of a cephalic tumour, pancreatoduodenectomy was carried
out (Whipple: 14 cases, pylorus-preserving: 40 cases). Exclusion
criteria for our analyses were perioperative mortality and the
presence of macroscopic residual disease after resection.
Data on clinical parameters, including sex, age, preoperative
assessment of disease state and type of operative procedure, were
gathered retrospectively from patient records. Pathologic findings
(tumour size, tumour location, involvement of surrounding
structures and lymph node status) were obtained from the
pathologists’ original reports. In addition to the original pathology
reports, microscopic findings (tumour type, degree of differentia-
tion and TNM classification) were reassessed.
Tumours were categorised as International Union Against
Cancer (Sobin and Wittekind, 2002).
Survival was determined from the date of initial surgery. Follow-
up was available for all patients. Subjects who died because for
causes other than pancreatic cancer during the follow-up period
were considered for survival analysis.
Histology
The formalin-fixed, paraffin-embedded samples were sectioned at
5mm and stained with haematoxylin and eosin. The histological
diagnosis was re-examined. In addition, the most representative
blocks were selected to be cut into 5 new mm-thick sections for
immunohistochemical studies.
Immunohistochemistry and quantification of the
immunoreactivity
Immunohistochemical studies were performed on 5-mm sections
by a streptavidin-biotin-peroxidase system using a commercial
kit (UCS Diagnostic, West Logan, UT, USA), according to the
manufacturer’s instructions. In brief, sections were de-paraffinised
and antigen retrieval was achieved by steaming slides for 35min in
citrate buffer pH 6. Endogenous peroxidase was blocked using 3%
hydrogen peroxide solution in PBS for 5min. The following
primary antibodies were used: rabbit polyclonal anti-Survivin
(ABcam, Cambridge, UK), goat polyclonal anti-Cox-2 (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA). Sections were counter-
stained with haematoxylin and mounted. The primary antibody
was replaced with rabbit or goat preimmune serum as a negative
control for nonspecific staining. The stained sections were
observed using a light microscope, and positivity was determined
by cell staining.
Antigens were quantified according to the following two
parameters: (1) the number of positively stained cells; (2) the
intensity of the staining, ranging from pale pink to dark orange.
Therefore, Cox-2 and Survivin positivity was graded on the basis
of the intensity and the number of positive cells: 0: negative; þ1:
weak to moderate positive affecting less than 50% of the tumour
area; þ2: weak to moderate positive on the majority of the tumour
or strong positive in the minority of the tumour; and þ3: strong
positive in the majority of the tumour area. The specimens with a
grade amounting to more than þ1 were regarded as positive, and
0 grade as negative. These scores were performed in a blinded
fashion.
Detection of apoptosis
Apoptotic cells were identified by the terminal deoxynucleotidyl
transferase (TdT)-mediated deoxyuridine triphosphate biotin
nick-end labelling (TUNEL) method. Dewaxed and rehydrated
specimens were incubated in proteinase K 40mgml
 1 for 1h at
371C and were treated with 3% H2O2 in methanol for 30min at
room temperature. After adding equilibration buffer for 5min at
room temperature, TdT enzyme was pipetted onto the sections and
incubated at 371C for 2h. The reaction was stopped by incubating
the sections in stop buffer for 30min at 371C. Antidigoxigenin
peroxidase was added to the slides, followed by incubation for
30min at 371C. Slides were stained with diaminobenzine for
10min and counterstained with haematoxylin. A total of 500 cells
were counted in each specimen. The apoptotic index was defined
as follows: apoptotic index (%)¼100 apoptotic cells/total cells.
We stratified tumour specimens according to TUNEL staining in
o10% or 410% stained cells.
Statistical analysis
The Spearman correlation test was used to assess the relationship
between original ordinal data before binary re-categorisations
(correlation matrix between immunostaining parameters). A
univariate survival analysis for each prognostic variable on
overall survival was estimated according to the Kaplan–Meier
method (Kaplan and Meier, 1958). The terminal event was death
attributable to cancer or noncancer causes. The statistical
significance of the differences in survival distribution among the
prognostic groups was evaluated by the log-rank test (Peto et al,
1977). The Cox proportional hazards model was applied to the
multivariate survival analysis (Cox, 1972). The prognostic
variables on overall survival included age, gender, T factor, N
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nuclear Survivin expression and Cox-2 staining. P-values o0.05
was regarded as statistical significant in two-tailed tests. SPSS
software (version 10.00, SPSS, Chicago) was used for statistical
analysis.
RESULTS
Patients’ characteristics
The cohort (Table 1) consisted of 67 patients with the diagnosis
of PDC (45 men and 22 women). All patients underwent
surgical resection of the tumour. The median age at diagnosis
was 63 years (range 45–83). Histopathological tumours features
are summarised in Table 1.
Median follow-up after surgery was 22 months (range: 3–100
months). The minimum follow-up for patients without tumour
recurrence was 9 months. In total, 14 patients were still alive at
census-taking (July 2004).
Of the 67 patients, 42 (93.3%) died of pancreatic cancer
and three (6.7%) of other causes. No patient was lost during the
follow-up.
The overall median survival time was 18.5 months (range: 3–92
months). The overall 1-year disease-specific survival rate was
76.2%, with a 5-year survival rate of 22.8%.
Adjuvant therapy has not been routinely offered in the hospitals
involved in the study. We identified 28 (41.8%) of 67 patients who
received any form of adjuvant chemotherapy within 3 months of
their operation and 19 patients (28.4%) who received adjuvant
radiotherapy. Chemoradiation was administered in 11 patients
(17.5%). No patients were treated with preoperative concomitant
chemoradiation.
Protocols for chemotherapy were not standardised, but chemo-
therapy was 5-fluorouracil or gemcitabine-based.
Cox-2, Survivin and TUNEL staining
Table 2 presents summary results from immunohistochemical
analysis of the 67 patients included in the study. The expression
analysis of Survivin revealed that in 42 out of 67 (62.7%)
specimens, no nuclear expression was recorded, while in 37
(55.2%) specimens the cytoplasmic staining for Survivin was
negative.
Moreover, 32 (47.8%) cases were considered as positive for
Cox-2 staining. Cox-2 expression was always cytoplasmic. In 28
(41.8%) pancreatic cancer specimens, TUNEL staining was present
in more than 10% of the observed cancer cells. Figure 1 shows the
pictures of immunohistochemical staining for the molecular
markers investigated in the present paper.
Immunohistochemical and clinico-pathological parameters
and patient survival
According to our analysis, univariate analysis showed that overall
survival is influenced by the Survivin expression and cellular
distribution. In particular, those patients with positive staining for
nuclear Survivin showed longer overall survival than those with
negative nuclear Survivin expression (10.00 vs 27.00; P¼0.0009).
On the contrary, patients with cytoplasmic Survivin expression
revealed a statistically significant shorter overall survival time
when compared with those with negative staining (10.00 vs 25.00;
P¼0.0127). The median survival time in patients with low
apoptotic index, evaluated by the TUNEL method, was 20.00 vs
8.00 months in those with high index (P¼0.0142), while Cox-2
staining did not influence the overall survival time (Table 3).
Figure 2 includes Kaplan–Meier survival plots in relation to
clinico-pathologic patients’ features. The only parameter that
significantly correlated with overall survival time was the presence
of metastatic lymph nodes (P¼0.0202). Adjuvant therapy did not
show any influence on overall survival (any adjuvant therapy:
P¼0.2048; postoperative chemotherapy: P¼0.4790; radiotherapy:
P¼0.1102). However, those patients who received chemoradiation
as adjuvant therapy after resection showed a longer median overall
survival (19.00 months) than those patients who did not (13.00
months), even if this difference does not reach a statistical
Table 1 Patients’ characteristics
Total number 67
Median age (range) 63 (45–83) years
Gender
Male vs female 45 vs 22 (67.2 vs 32.8%)
Pancreatic cancer site
Head 54 (80.6%)
Tail/body 6 (9.0%)
Diffuse 7 (10.4%)
Factor
T1 8 (11.9%)
T2 17 (25.4%)
T3 40 (59.7%)
N factor
Negative 33 (49.3%)
Positive 34 (50.7%)
Grading
Well differentiated 14 (20.9%)
Moderate differentiated 28 (41.8%)
Poor differentiated 15 (22.3%)
Postoperative radiotherapy
Yes 19 (28.4%)
No 48 (71.6%)
Postoperative chemotherapy
Yes 28 (41.8%)
No 39 (58.2%)
Postoperative chemoradiation
Yes 11 (16.4%)
No 56 (83.6%)
Median follow-up time (median; range) 12 (7–112) months
Median overall survival (median; range) 18.5 (3–98) months
Table 2 Immunohistochemical parameters pancreatic adenocarcinoma
patients
Number %
Nuclear Survivin expression
Survivin negative 42 62.7
Survivin positive 25 37.3
Nuclear survivin expression
Survivin negative 37 55.2
Survivin positive 30 44.8
Cox-2 expression
Cox-2 negative 35 52.2
Cox-2 positive 32 47.8
TUNEL staining
TUNEL o10 39 58.2
TUNEL 410 28 41.8
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ssignificance (P¼0.0960). Probably, this non statistically significant
difference is due to the small number of patients who received
chemoradiation.
Figure 3 depicts Kaplan–Meier survival plots for all patients
showing the relation between either Cox-2 staining (A), the
apoptotic index (B), nuclear (C) and cytoplasmic (D) Survivin
expression and clinical outcome.
By a multivariate Cox regression analysis, the only immuno-
histochemical parameter that significantly influenced overall
survival was the Survivin expression by cells. Both nuclear and
cytoplasmic expression of Survivin resulted statistically significant
prognostic factors at the multivariate analysis. The calculated
relative risk in patients with positive nuclear staining was lower
than in patients with negative staining (0.430; P¼0.002). However,
the positive cytoplasmic staining for Survivin in this cohort of
patients was a statistically significant negative prognostic factor. In
particular, the relative risk in patients with negative Survivin
staining was 0.056 when compared with the risk of patients with
positive cytoplasmic staining patients (P¼0.040) (see Table 4).
DISCUSSION
Pancreatic cancer is a very aggressive neoplasm with very poor
prognosis. Surgical treatment is the only therapeutic option
potentially able to cure this tumour. However, in more than 80%
of cases showing pancreatic cancer, patients cannot undergo
surgical treatment because of clinically advanced disease. Non-
surgical treatments offer little, if any, survival advantage. As a
result, mortality almost parallels its incidence, with a 5-year
survival rate of less than 10% (Kimura et al, 1998). There are only
few substantial data reporting clinical significant prognostic
markers for pancreatic cancer patients. Sohn et al (2000) showed
by multivariate analysis that negative resection margins, tumour
size and differentiation were important independent prognostic
indicators. Similarly, Geer and Brennan (1993) demonstrated
prognostic significance of tumour size, differentiation and lymph
A B
D C
Figure 1 (A) Cytoplasmic positivity of immunohistochemical staining of Cox-2 ( 40); (B) cytoplasmic positivity of immunohistochemical staining of
Survivin ( 20), with an enlarged particular showing the peculiar cytoplasmic staining; (C) nuclear positivity of immunohistochemical staining of Survivin
( 20) with an enlarged particular showing the peculiar nuclear staining; (D) TUNEL nuclear positive staining ( 400).
Table 3 Univariate analysis of survival in radically operated pancreatic
adenocarcinoma patients
Median survival (months) 95% CI P-value
Gender
Female 13.00 7.99–18.01 0.4020
Male 19.00 13.40–24.60
Age
o65 years 12.00 10.23–13.77 0.2890
465 years 22.00 16.36–27.64
T factor
T1–2 21.00 4.71–37.29 0.4360
T3 16.00 11.67–20.33
N factor
N0 24.00 9.12–34.88 0.0202
N+ 13.00 9.70–16.30
Adjuvant therapy
No adjuvant therapy 15.00 12.33–19.34 P¼0.2048
Any adjuvant therapy 22.00 13.67–28.11
Nuclear Survivin expression
Survivin negative 10.00 10.34–13.66 0.0009
Survivin positive 27.00 20.03–31.97
Cytoplasmic Survivin expression
Survivin negative 25.00 8.87–29.66 0.0127
Survivin positive 10.00 7.34–17.65
Cox-2 expression
Cox-2 negative 18.00 8.07–27.93 0.657
Cox-2 positive 17.00 10.83–23.17
TUNEL staining
TUNEL o10 24.00 14.42–25.58 0.0142
TUNEL 410 11.00 2.55–13.45
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Nitecki et al (1995) from the Mayo Clinic showed that 5-year
survival was significantly greater for node-negative vs node-
positive patients (14 vs 1%), and for patients with smaller tumours
vs patients with larger tumours (20 vs 1%). Moreover, in this
paper, a combination of node-negativity and lack of perineural or
duodenal invasion constituted a significant prognostic marker
(Nitecki et al, 1995). Finally, Kawesha et al (2000) demonstrated
that significant prognostic factors in pancreatic cancer patients
were TNM stage of disease and lymph node involvement.
In addition, preoperative estimation of tumour size and lymph
node involvement is difficult. As a consequence, patient selection
for surgical resection based on preoperative estimation of these
parameters often results inappropriate.
Much more interest is now focused on the role of molecular
markers to select patients with better prognosis and those who
could benefit of more aggressive treatments. Dysregulation of the
normal cell-cycle regulatory machinery and of apoptosis mecha-
nisms are integral to the neoplastic process, and there is now
compelling evidence implicating loss of cell-cycle control in the
development and progression of most human cancers (Sherr,
1996).
In the present paper we investigated the prognostic role of
Survivin overexpression, Survivin cellular localisation and Cox-2
staining in a uniform cohort of patients affected by pancreatic
cancer treated with radical surgery. These factors have been
evaluated in conjunction with TUNEL staining for the detection of
apoptotic cells.
In our analysis we identified for the first time that a different
prognostic role is played by the nuclear and cytoplasmic Survivin
expression. In particular, the nuclear expression of Survivin
identified patients with a good prognosis, while the cytoplasmic
overexpression of Survivin is a negative prognostic factor. These
findings have been confirmed by univariate and multivariate
analysis of survival.
There are some conflicting data published about the role of
Survivin overexpression in cancer patients.
Cytoplasmic Survivin immunoreactivity has been observed in
the vast majority of human tumours and it has been constantly
associated with poor prognosis (Altieri et al, 1999).
Previous data suggested that Survivin is accumulated in
advanced tumour stages, thus suggesting that its expression tends
to increase with tumour progression. This evidence could justify
the poor prognosis of human cancer with high cytoplasmic
Survivin expression (Adida et al, 1998b; Swana et al, 1999; Ito et al,
2000).
Scarce data are available regarding Survivin nuclear localisation
in human tumours. Interestingly, nuclear Survivin localisation in
gastric (Okada et al, 2001) and transitional cell carcinoma (Lehner
et al, 2002) is considered predictive of a favourable prognosis.
Recently, Survivin has been detected in the nucleus of non-small-
cell lung cancer cells from clinical samples, without any significant
relation with clinical outcome (Falleni et al, 2003).
Finally, in two recent papers, nuclear Survivin overexpression
has been associated with poor prognosis in mantle cell lymphoma
(Martinez et al, 2004) and oesophageal squamous cell carcinoma
(Grabowski et al, 2003). The results of these studies contributed to
the confusion regarding the role of nuclear expression of Survivin.
The reason for the different subcellular location of Survivin in
different cancers is unclear. A recent report by Fortugno et al
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Figure 2 Kaplan–Meier survival curves for radically resected pancreatic cancer patients: (A) age (o65 years vs 4 65 years); (B) N stage (nodal
involvement vs no nodal involvement); (C) adjuvant therapy (any adjuvant therapy vs no adjuvant therapy); (D) T stage (T1–2 vs T3).
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s(2002) showed that Survivin exists in two distinct subcellular pools
(cytoplasm and nucleus). The two Survivin pools are immuno-
chemically distinct and independently modulated during cell cycle
progression. The immunochemical differences between nuclear
and cytosolic Survivin may explain, in part, the conflicting data
about Survivin localisation reported in the literature and its
prognostic role. In fact, two regions in Survivin that exhibit
strikingly differential antibody reactivity were identified by
Fortugno et al (2002): Cys
57-Trp
67, which is exposed in cytosolic
and centrosome-associated survivin, but masked in nuclear and
microtubulebound survivin, and Ala
3-Ile
19, which is accessible in
kinetochore-associated Survivin, but not in the cytosolic form. A
plausible interpretation of these data is that separate post-
translational modifications may differentially affect epitope
accessibility of nuclear vs cytosolic/microtubule-bound Survivin
in vivo.
The mechanisms for the shift in the intracellular distribution
of Survivin and its nuclear translocation in human cancer cells are
still unclear. Suzuki et al found that the nuclear translocation
in HepG2 cells is dependent both on Fas stimulation and cell
proliferation. Survivin interacts with Cdk4 on translocation to
nucleus, which releases p21 from the cdk4/p21 complex, forming a
procaspase 3/p21 complex that resists Fas-mediated cell death
(Suzuki et al, 2000). Rodriguez et al proposed that the subcellular
distribution of survivin is regulated by an active import into the
nucleus and a CRM1-mediated export to the cytoplasm, suggesting
that survivin may be considered a nuclear shuttling protein.
Predominantly cytosolic localisation in a high number of tumours
may be the result of a high rate of nuclear export (Rodriguez et al,
2002).
Our study also explored the prognostic role of Cox-2 in our
patients. Recently, Krysan et al (2004) have reported a frequent
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Figure 3 Kaplan–Meier survival curves for radically resected pancreatic cancer patients: (A) Cox-2 expression (positive Cox-2 expression vs negative
Cox-2 expression); (B) TUNEL staining (410 vs o10%); (C) nuclear Survivin expression (positive nuclear Survivin expression vs negative nuclear Survivin
expression); (D) cytoplasmatic Survivin expression (positive cytoplasmatic Survivin expression vs negative cytoplasmatic Survivin expression).
Table 4 Multivariate analysis of survival in radically operated pancreatic
adenocarcinoma patients
Relative risk 95% CI P
N factor
N+ 1 — 0.145
N0 0.745 0.363–1.160
Nuclear Survivin expression
Survivin negative 1 0.211–0.897 0.002
Survivin positive 0.430
Cytoplasmic Survivin expression
Survivin positive 1 0.325–0.901 0.040
Survivin negative 0.556
TUNEL staining
TUNEL410 1 0.451–1.430 0.105
TUNEL o10 0.670
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patients. As a consequence of these findings, we explored the
prognostic impact of Cox-2 in pancreatic cancer patients in
association with Survivin overexpression. Our findings do not
suggest any role of Cox-2 in determining the clinical outcome in
radically resected pancreatic cancer patients.
Finally, we evaluated the prognostic role of apoptotic index. Our
investigation revealed that patients with higher apoptotic index
benefit of a longer median survival time if compared with those
with lower apoptotic index. However, when evaluated in multi-
variate analysis, the apoptotic index did not maintain a statistical
significant value on prognosis. Only few data are available about
the prognostic role of the apoptotic index in pancreatic cancer
patients. Sarela et al (2002) failed to identify any prognostic
relevance of apoptotic index in pancreatic adenocarcinoma
patients (advanced or radically resected). Separately, Nio et al
(2001) confirmed that apoptotic index has not a prognostic role in
a cohort of 66 radically resected pancreatic cancer patients.
In conclusion, the present study is the first report that
established the prognostic relevance of the Survivin expression
in pancreatic cancer in relation with its cellular distribution. The
knowledge of the factors that have an independent influence on
prognosis is crucial for the development and interpretation of
prospective randomised trials in which radically operated pan-
creatic cancer patients are stratified and treated with adjuvant
therapies according to these prognostic determinants.
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